Selective serotonin reuptake inhibitors (SSRIs) are prescribed for the treatment of depression worldwide. SSRIs are suspected to increase the risk of suicidal ideation and behavior (suicidality) in children, adolescents, and young adults. We examined the association between SSRI therapy and suicidality by applying a logistic regression model to age-stratified data from the Food and Drug Adminis...

CLINICAL QUESTION Are selective serotonin reuptake inhibitors (SSRIs) associated with better recovery after stroke? BOTTOM LINE SSRIs may be associated with improved recovery after stroke, even in persons without depression. However, much of the evidence is of poor quality. Large, high-quality trials are needed to evaluate the validity of the current evidence and improve precision of estimate...

Precisely how SSRIs induce long-term modifications in serotonin transmission to elicit their antidepressant actions is unclear. In this issue of Neuron, Issler et al. (2014) identify a key role for microRNA-135a [corrected] in the raphe nuclei in the molecular mechanisms underlying the therapeutic actions of SSRIs.

BACKGROUND Selective serotonin reuptake inhibitors (SSRIs) are popular medications for anxiety and depression, but their effectiveness, particularly in patients with prominent symptoms of loss of motivation and pleasure, has been questioned. There are few studies of the effect of SSRIs on neural reward mechanisms in humans. METHODS We studied 45 healthy participants who were randomly allocate...

BACKGROUND Experimental animal studies and one population-based study have suggested an increased risk for adverse neurodevelopmental outcome after prenatal exposure to SSRIs. We describe the methods and design of a population-based study examining the association between prenatal SSRI exposure and neurodevelopment until age 14. METHODS AND DESIGN This is a cohort study of national registers ...

Clinical research has demonstrated differential efficacy of selective serotonin reuptake inhibitors (SSRIs) and norepinephrine reuptake inhibitors (NRIs), which may relate to differential acute effects these medications have on emotional brain processes. Here we present findings from a Multi-Level Kernel Density Analysis meta-analysis that integrates and contrasts activations from disparate fMR...

Depression associated with Parkinson’s disease (PD) is very common and by some estimates, affects 40%-50% of that population. The majority of these patients are treated with a selective serotonin reuptake inhibitor (SSRI). However, extrapyamidal adverse reactions are a side-effect of this medication and by causing inhibition of the dopaminergic path way, these medications could potentially wors...

Antidepressants, specifically Selective Serotonin Reuptake Inhibitors (SSRis ), have been used to treat a plethora of neurological diseases, such as major depressive disorder (MDD)and obsessive compulsive disorder (OCD). 1 The first SSRI medication available for prescription was Eli Lilly Company's Prozac, which received Food and Drug Administration (FDA) approval in 1987.2 Initially, SSRis wer...

Cognitive and psychomotor impairment are important considerations in the treatment of depression in the elderly due to both the underlying slowing of cognitive and psychomotor processes as a normal function of aging and the superimposed deficits associated with the disease itself. Only the latter are reversible with effective antidepressant therapy. Yet certain antidepressant drugs possess seda...

Selective serotonin reuptake inhibitors (SSRIs) have become the most popular antidepressants over the last decade, largely because they have a better side effect profile than the medications that were widely used previously, the tricyclic antidepressants (TCAs) and the monoamine oxidase inhibitors (MAOIs). The SSRIs mostly have one main mechanism of action, inhibition of serotonin reuptake. A f...